In addition to the well-known strategies of antibiotic resistance and biofilm formation,
bacterial populations possess an additional survival strategy to endure hostile environments …

With the increasing number of cases of inactive and drug-resistance tuberculosis, there is an
urgent need to develop new potent molecules set for fighting this brutal disease. Medicinal …

Mycobacterium tuberculosis (Mtb) infection is notoriously difficult to treat. Treatment efficacy
is limited by Mtb's intrinsic drug resistance, as well as its ability to evolve acquired resistance …

Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …

Tuberculosis (TB) has been considered as the highly chronic, contagious and infectious
disorder caused by Mycobacterium tuberculosis (Mtb). Every year more than 10 million …

New antibiotics are urgently needed to address the mounting resistance challenge. In early
drug discovery, one of the bottlenecks is the elucidation of targets and mechanisms. To …

With the increasing number of cases of latent and drug resistant tuberculosis, there is an
urgent need to develop new, potent molecules capable of combating this deadly disease …

The lipoteichoic acid (LTA) biosynthesis pathway has emerged as a promising antimicrobial
therapeutic target. Previous studies identified the 1, 3, 4 oxadiazole compound 1771 as an …

Bacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during
translation have been proposed as novel antibiotic targets because they are essential in …

Despite having a highly reduced genome, Chlamydia trachomatis undergoes a complex
developmental cycle in which the bacteria differentiate between the following two …